| abstract |
The invention belongs to the technical field of biological medicines, and particularly relates to FGF18 gene modified mesenchymal stem cells, a preparation method thereof and application thereof in treating osteoarthritis. The invention discloses a FGF18 gene modified mesenchymal stem cell, which is an umbilical cord mesenchymal stem cell over-expressing FGF18 without influencing the phenotype and differentiation capacity of MSC. By using the modified mesenchymal stem cells to over-express FGF18 gene and using a variant or autologous local joint cavity injection mode to treat osteoarthritis, the cartilage defect of arthritis patients can be fundamentally improved, the curative effect is improved, and the pain and the side effect of the patients in the treatment process are reduced. The invention provides technical support for preparing the medicament for promoting the osteoarthritis repair. |